Literature DB >> 32640349

The liver fibrosis niche: Novel insights into the interplay between fibrosis-composing mesenchymal cells, immune cells, endothelial cells, and extracellular matrix.

Michitaka Matsuda1, Ekihiro Seki2.   

Abstract

Liver fibrosis is a hepatic wound-healing response caused by chronic liver diseases that include viral hepatitis, alcoholic liver disease, non-alcoholic steatohepatitis, and cholestatic liver disease. Liver fibrosis eventually progresses to cirrhosis that is histologically characterized by an abnormal liver architecture that includes distortion of liver parenchyma, formation of regenerative nodules, and a massive accumulation of extracellular matrix (ECM). Despite intensive investigations into the underlying mechanisms of liver fibrosis, developments of anti-fibrotic therapies for liver fibrosis are still unsatisfactory. Recent novel experimental approaches, such as single-cell RNA sequencing and proteomics, have revealed the heterogeneity of ECM-producing cells (mesenchymal cells) and ECM-regulating cells (immune cells and endothelial cells). These approaches have accelerated the identification of fibrosis-specific subpopulations among these cell types. The ECM also consists of heterogenous components. Their production, degradation, deposition, and remodeling are dynamically regulated in liver fibrosis, further affecting the functions of cells responsible for fibrosis. These cellular and ECM elements cooperatively form a unique microenvironment: a fibrotic niche. Understanding the complex interplay between these elements could lead to a better understanding of underlying fibrosis mechanisms and to the development of effective therapies.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Extracellular matrix; Hepatic stellate cells; Hyaluronic acid; Immune cells; Liver sinusoidal endothelial cells; Myofibroblasts

Mesh:

Substances:

Year:  2020        PMID: 32640349      PMCID: PMC7484466          DOI: 10.1016/j.fct.2020.111556

Source DB:  PubMed          Journal:  Food Chem Toxicol        ISSN: 0278-6915            Impact factor:   6.023


  251 in total

Review 1.  Lysyl oxidase: properties, specificity, and biological roles inside and outside of the cell.

Authors:  Herbert M Kagan; Wande Li
Journal:  J Cell Biochem       Date:  2003-03-01       Impact factor: 4.429

Review 2.  Regulation of PDGF and its receptors in fibrotic diseases.

Authors:  James C Bonner
Journal:  Cytokine Growth Factor Rev       Date:  2004-08       Impact factor: 7.638

Review 3.  Macrophage activation by endogenous danger signals.

Authors:  X Zhang; D M Mosser
Journal:  J Pathol       Date:  2008-01       Impact factor: 7.996

Review 4.  Tissue-Resident Macrophage Ontogeny and Homeostasis.

Authors:  Florent Ginhoux; Martin Guilliams
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

5.  Expression of platelet-derived growth factor and its receptors in normal human liver and during active hepatic fibrogenesis.

Authors:  M Pinzani; S Milani; H Herbst; R DeFranco; C Grappone; A Gentilini; A Caligiuri; G Pellegrini; D V Ngo; R G Romanelli; P Gentilini
Journal:  Am J Pathol       Date:  1996-03       Impact factor: 4.307

6.  Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment.

Authors:  Vivian Barry-Hamilton; Rhyannon Spangler; Derek Marshall; Scott McCauley; Hector M Rodriguez; Miho Oyasu; Amanda Mikels; Maria Vaysberg; Haben Ghermazien; Carol Wai; Carlos A Garcia; Arleene C Velayo; Brett Jorgensen; Donna Biermann; Daniel Tsai; Jennifer Green; Shelly Zaffryar-Eilot; Alison Holzer; Scott Ogg; Dung Thai; Gera Neufeld; Peter Van Vlasselaer; Victoria Smith
Journal:  Nat Med       Date:  2010-09-05       Impact factor: 53.440

7.  Liver fibrosis induced by hepatic overexpression of PDGF-B in transgenic mice.

Authors:  Piotr Czochra; Borut Klopcic; Erik Meyer; Johannes Herkel; Jose Francisco Garcia-Lazaro; Florian Thieringer; Peter Schirmacher; Stefan Biesterfeld; Peter R Galle; Ansgar W Lohse; Stephan Kanzler
Journal:  J Hepatol       Date:  2006-05-30       Impact factor: 25.083

8.  Inhibition of the CXCL12/CXCR4 chemokine axis with AMD3100, a CXCR4 small molecule inhibitor, worsens murine hepatic injury.

Authors:  Yedidya Saiman; JingJing Jiao; M Isabel Fiel; Scott L Friedman; Costica Aloman; Meena B Bansal
Journal:  Hepatol Res       Date:  2014-10-07       Impact factor: 4.288

Review 9.  Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets.

Authors:  A M Gressner; R Weiskirchen
Journal:  J Cell Mol Med       Date:  2006 Jan-Mar       Impact factor: 5.310

10.  Neutrophils alleviate fibrosis in the CCl4-induced mouse chronic liver injury model.

Authors:  Eiko Saijou; Yutaka Enomoto; Michitaka Matsuda; Cindy Yuet-Yin Kok; Shizuo Akira; Minoru Tanaka; Atsushi Miyajima
Journal:  Hepatol Commun       Date:  2018-04-12
View more
  4 in total

1.  Higher Levels of Plasma Hyaluronic Acid and N-terminal Propeptide of Type III Procollagen Are Associated With Lower Kidney Function in Children With Non-alcoholic Fatty Liver Disease.

Authors:  Antonella Mosca; Alessandro Mantovani; Annalisa Crudele; Nadia Panera; Donatella Comparcola; Rita De Vito; Marzia Bianchi; Christopher D Byrne; Giovanni Targher; Anna Alisi
Journal:  Front Pediatr       Date:  2022-06-06       Impact factor: 3.569

2.  Heterogeneous microenvironment analysis to explore the potential regulatory role of endothelial-mesenchymal transition in idiopathic pulmonary fibrosis.

Authors:  Yinning Xu; Xiaoping Hu; Yiwen Zhang; Zongfu Pan; Zhiyong Sun; Zhongjie Huang; Shuilian Zheng; Hansheng Pan; Xiaozhou Zou; Ping Huang
Journal:  Ann Transl Med       Date:  2022-04

3.  Indoleamine 2,3-dioxygenase 1 limits hepatic inflammatory cells recruitment and promotes bile duct ligation-induced liver fibrosis.

Authors:  Chan Mo; Shuwen Xie; Bin Liu; Weichao Zhong; Ting Zeng; Sha Huang; Yuqi Lai; Guanghui Deng; Chuying Zhou; Weixin Yan; Yuyao Chen; Shaohui Huang; Lei Gao; Zhiping Lv
Journal:  Cell Death Dis       Date:  2021-01-07       Impact factor: 8.469

4.  Identification of potential targets of the curcumin analog CCA-1.1 for glioblastoma treatment : integrated computational analysis and in vitro study.

Authors:  Adam Hermawan; Febri Wulandari; Naufa Hanif; Rohmad Yudi Utomo; Riris Istighfari Jenie; Muthi Ikawati; Ahmad Syauqy Tafrihani
Journal:  Sci Rep       Date:  2022-08-17       Impact factor: 4.996

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.